Stockscreener 앱 받기
36.18
0.54%
0.181
전일 마감가:
$36.00
열려 있는:
$36
하루 거래량:
1.50M
Relative Volume:
0.40
시가총액:
$15.65B
수익:
$2.31B
순이익/손실:
$1.66B
주가수익비율:
15.73
EPS:
2.3
순현금흐름:
$827.02M
1주 성능:
+0.49%
1개월 성능:
+2.97%
6개월 성능:
+11.54%
1년 성능:
+30.01%
1일 변동 폭
$35.79
$36.23
1주일 범위
$35.23
$36.36
52주 변동 폭
$24.05
$38.00
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.20 | 15.56B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.65 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.71 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.68 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
819.25 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.03 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
What’s the recovery path for long term holders of Royalty Pharma plcMarket Risk Analysis & Safe Capital Growth Trade Ideas - newser.com
Morningstar Investment Management LLC Acquires Shares of 8,307 Royalty Pharma PLC $RPRX - MarketBeat
What indicators show strength in Royalty Pharma plcJuly 2025 Movers & Breakout Confirmation Trade Signals - newser.com
Callan Family Office LLC Buys Shares of 16,418 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Valuation: Is There More Upside After This Year’s 40% Rally? - Yahoo Finance
Royalty pharma projects 6-12% growth in 2025 portfolio receipts with $2B share buyback plan - MSN
Why retail investors pile into Royalty Pharma plc stockQuarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
Royalty Pharma plc (RPRX) Stock Analysis: Unveiling a 23.59% Upside Potential in the Biotech Royalty Space - DirectorsTalk Interviews
Is this a good reentry point in Royalty Pharma plcQuarterly Investment Review & AI Forecasted Stock Moves - newser.com
Royalty Pharma PLC $RPRX Shares Sold by Board of the Pension Protection Fund - MarketBeat
Inspire Investing LLC Buys 22,436 Shares of Royalty Pharma PLC $RPRX - MarketBeat
What candlestick patterns are forming on Royalty Pharma plcJuly 2025 Setups & Risk Managed Investment Signals - newser.com
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
KLP Kapitalforvaltning AS Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Belpointe Asset Management LLC Purchases New Position in Royalty Pharma PLC $RPRX - MarketBeat
Why Royalty Pharma plc (RPD) stock could rally stronglyJuly 2025 Sector Moves & Risk Controlled Stock Alerts - newser.com
Royalty Pharma To Announce Third Quarter 2025 Financial Results On November 5, 2025 - TradingView
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
Q3 2025 Results Nov 5: Royalty Pharma to Report Results and Host Call/Webcast at 8:00 a.m. ET - Stock Titan
Custom watchlist performance reports with Royalty Pharma plcPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Royalty Pharma (NASDAQ:RPRX) Raised to Buy (B-) at Weiss Ratings - MarketBeat
Is Royalty Pharma plc stock a smart buy before Fed meeting2025 Top Gainers & AI Enhanced Execution Alerts - newser.com
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Yahoo Finance
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - sharewise.com
Why Royalty Pharma plc stock is a must watch in 2025Weekly Trading Summary & AI Optimized Trade Strategies - newser.com
Understanding Royalty Pharma plc’s price movementMarket Growth Review & Accurate Technical Buy Alerts - newser.com
Royalty Pharma (RPRX) Stock Analysis: Unlocking a 23.72% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
A Look at Royalty Pharma’s (RPRX) Valuation Following Imdelltra Royalty Acquisition and Board Enhancement - Sahm
Will Royalty Pharma plc stock see PE expansion2025 Analyst Calls & AI Driven Price Predictions - newser.com
Royalty Pharma collaborates with Biogen for R&D funding - MSN
Royalty Pharma PLC $RPRX Position Increased by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Will Royalty Pharma's (RPRX) Governance Shift Sharpen Its Edge in Life Sciences Investment? - simplywall.st
The Goldman Sachs Group Initiates Coverage on Royalty Pharma (NASDAQ:RPRX) - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Goldman Sachs initiates Royalty Pharma stock with Buy rating, $42 target - Investing.com Nigeria
Royalty Pharma : Q3 2025 Pre-Quarterly Results Communication - MarketScreener
Goldman Sachs Initiates Coverage of Royalty Pharma (RPRX) with Buy Recommendation - Nasdaq
Royalty Pharma plc Stock Analysis and ForecastPrice Action Analysis & High Profit Investment Ideas - earlytimes.in
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.21%
0.90%
자본화:
|
볼륨(24시간):